Format

Send to

Choose Destination
Am J Hematol. 2009 Mar;84(3):140-3. doi: 10.1002/ajh.21342.

Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.

Author information

1
Cattedra ed UO di Ematologia con Trapianto, Università degli Studi di Palermo, Italy.

Abstract

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF.

PMID:
19123461
DOI:
10.1002/ajh.21342
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center